Recent 8-K filings for BG
Highest-materiality recent filing
Bunge completes merger with Viterra, creating global agribusiness solutions company
- Bunge acquired all outstanding Viterra shares, issuing 65.6M shares valued at ~$5.3B plus $2B cash to Sellers.
- Sellers include Glencore, CPPIB, BCI; they collectively now own ~33% of Bunge's registered shares.
-
Bunge shareholders approve $2.88 annual dividend and reelect all 12 directors at 2026 AGM
Aggregate dividend of $2.88/share in four equal installments approved (171.8M votes for, 34.6K against).
-
Bunge Q1 adjusted EPS $1.83 beats prior year; raises FY outlook to $9.00-9.50
Q1 GAAP diluted EPS $0.35 vs $1.48 prior year; adjusted EPS $1.83 vs $1.81.
-
Bunge expands securitization program by $500M to $2B, adds U.S. and Canadian sellers
Aggregate program size increased $500M to $2B; accordion feature decreased from $1B to $500M.
-
Bunge Global SA grants PBRSUs to execs tied to Viterra integration synergy targets
CEO Gregory Heckman receives 63,281 PBRSUs; CFO John Neppl receives 12,099; COO Garros 19,501.
-
Bunge Global SA announces pricing of $1.2B senior notes offering
$500M of 4.800% notes due 2033 and $700M of 5.150% notes due 2036 issued by Bunge Limited Finance Corp.
-
Bunge files Viterra H1 2025 financials; Viterra reports $199M net loss on $20.97B revenue
Viterra H1 2025 revenue $20,974M (down 7% YoY from $22,572M); net loss $199M vs income $70M.
-
Bunge FY2025 GAAP EPS $4.93 (down 38%); Q4 adjusted EPS $1.99 near prior $2.13
Full-year GAAP diluted EPS $4.93 vs $7.99; adjusted $7.57 vs $9.19.
-
Bunge Global SA cancels 12.38M repurchased shares, reduces share capital by ~$123.8K
Share capital reduced from USD 2,208,943.73 to USD 2,085,117.63 via cancellation of 12,382,610 registered shares.
-
Bunge Global SA COO David Mattiske steps down; Julio Garros becomes sole COO effective Dec 12, 2025
David Mattiske resigns as co-Chief Operating Officer effective Dec 11, 2025, to pursue other professional opportunities.
-
Bunge Global extends securitization program termination date to Dec 2026
Extended trade receivables securitization program termination by 364 days to December 15, 2026.
-
Q3 GAAP diluted EPS $0.86 vs $1.56 YoY; adjusted EPS $2.27 vs $2.29.
-
Bunge changes segment reporting and recasts 2025 outlook after Viterra combination
Oilseeds realigned into Soybean Processing and Refining, Softseed Processing and Refining, and Other Oilseeds Processing and Refining.
-
Bunge enters $4.2B, $3.5B, $1.1B new credit facilities; terminates prior agreements
Bunge subsidiary BLFC entered $4.2B 5-year revolver maturing Oct 3, 2030, replacing $3.2B facility.
-
Bunge increases commercial paper program by $1.0B to $3.0B total
BLFC CP Program increased from $2.0B to $3.0B on September 3, 2025.
-
Bunge Global SA priced $1.3B senior notes in two tranches (4.550% 2030 and 5.150% 2035)
Issued $650M 4.550% Senior Notes due 2030 and $650M 5.150% Senior Notes due 2035 via Bunge Limited Finance Corp., guaranteed by Bunge.
-
Bunge Q2 GAAP EPS $2.61, adjusted $1.31; merger with Viterra completed
GAAP diluted EPS $2.61 vs $0.48 prior year; net income $354M vs $70M.
-
Bunge completes exchange of ~$1.92B Viterra notes for new Bunge-guaranteed notes
BLFC issued $579.8M 2% notes due 2026, $439.7M 4.9% due 2027, $598.6M 3.2% due 2031, $299.8M 5.25% due 2032.
-
Bunge completes Viterra acquisition; exchange offers expire, settlement July 8
Business combination with Viterra closed on July 2, 2025.
-
Bunge completes merger with Viterra, creating global agribusiness solutions company
Bunge acquired all outstanding Viterra shares, issuing 65.6M shares valued at ~$5.3B plus $2B cash to Sellers.
-
Bunge borrows $2B via term loan to fund Viterra acquisition; matures 2028
BLFC enters $2B term loan agreement with Sumitomo Mitsui Banking Corp as administrative agent; matures June 1, 2028.
-
Amends $3.2B US revolving credit facility; current commitments of $1.95B remain; incremental $1.25B available upon Viterra approval.
-
Bunge-Viterra merger closing set for July 2, 2025; Chinese, Mexican antitrust approvals received
Closing date mutually agreed as July 2, 2025, subject to satisfaction of remaining conditions.
-
Bunge extends Viterra note exchange offer to July 3, 2025, pending acquisition close
Expiration date extended from June 13 to July 3, 2025, for exchange of up to $1.95B in Viterra notes.
-
Bunge shareholders approve $2.80/year dividend, elect directors, including Linda Jojo
Cash dividend of $2.80 per share approved, payable in four equal installments.
-
Bunge Q1 adj EPS $1.81 vs $3.04 YoY; maintains FY guidance ~$7.75
GAAP diluted EPS $1.48 vs $1.68 prior year; adjusted EPS $1.81 vs $3.04.
-
Bunge extends Viterra notes exchange offer expiration to June 13, 2025
Expiration date extended from May 5, 2025 to June 13, 2025; further extensions possible if Viterra acquisition not closed.
-
Bunge extends Viterra note exchange offer expiration to May 5, 2025
Exchange offers and consent solicitations extended to 5:00 p.m. NY time on May 5, 2025 from April 7.
-
Bunge extends exchange offer deadline for Viterra notes to April 7, 2025, pending deal close
Bunge subsidiary extends expiration of exchange offers and consent solicitations from March 7 to April 7, 2025, for up to $1.95B in new notes and cash.
-
Bunge FY2024 adjusted EPS $9.19 vs $13.66; Q4 adjusted EPS $2.13 vs $3.70
Full-year GAAP diluted EPS $7.99 (2023: $14.87); adjusted EPS $9.19 vs $13.66.
-
Bunge extends expiration of Viterra notes exchange offers to March 7, 2025
Exchange offers for up to $1.95B aggregate principal of existing Viterra notes extended to March 7, 2025.
-
Bunge extends exchange offer expiration for Viterra notes to Feb 3, 2025
Expiration date extended from Jan 2, 2025 to Feb 3, 2025 for exchange offers and consent solicitations on up to $1.95B of Viterra notes.
-
Bunge Global SA cancels 6.1M repurchased shares, reduces share capital by $61k
Share capital reduced by $61,469.30 from $1,614,294.72 to $1,552,825.42.
-
Bunge extends trade receivables securitization program termination to Dec 2025
Twenty-Seventh Amendment extends termination date of existing securitization program by 364 days to December 16, 2025.
-
Bunge expands share repurchase program with additional $500M authorization to ~$1.3B total
Board authorized an additional $500M in share repurchases on November 13, 2024.
-
Bunge extends Viterra note exchange offers to Jan 2, 2025; 94-99% tendered
Exchange offer expiration extended from Oct 31, 2024 to Jan 2, 2025; all terms unchanged.
-
Bunge Q3 adjusted EPS $2.29 vs $2.99 YoY; full-year guidance at least $9.25
Q3 GAAP diluted EPS $1.56 vs $2.47; adjusted EPS $2.29 vs $2.99 in prior year.
-
Bunge extends Viterra note exchange offers to Oct 31; tender rates high
BLFC extends expiration date from Oct 7 to 5:00 p.m. NY time on Oct 31, 2024.
-
Bunge sells 50% stake in BP Bunge Bioenergia JV for ~$828M net
Sold 50% ownership in BP Bunge Bioenergia (sugar/ethanol JV) to BP affiliate for approx. $828M net.
-
Bunge announces early results: 94-98% of Viterra notes tendered in exchange offers up to $1.95B
Consents received: 96.5% on 2026/2031 notes, 97.6% on 2027/2032 notes; releases Viterra guarantees.
-
Bunge subsidiary issues $2B in senior notes to partly fund Viterra acquisition
$400M of 4.100% notes due 2028, $800M of 4.200% notes due 2029, $800M of 4.650% notes due 2034.
-
Bunge prices $2.0B senior notes offering in three tranches to fund Viterra acquisition
$400M 4.100% notes due 2028, $800M 4.200% notes due 2029, $800M 4.650% notes due 2034.
-
Bunge files Viterra FY2023 financials: revenue $54.7B, net income $453M (down 56% YoY)
Viterra 2023 revenue $54,673M; net income $453M vs $1,042M in 2022; gross margin $1,702M.
-
Bunge subsidiary launches up to $1.95B exchange offer for Viterra notes pending acquisition
BLFC offers to exchange all Viterra notes (2026/2027/2031/2032) for new Bunge-guaranteed notes plus $1 cash per $1,000.
-
Bunge Q2 adjusted EPS $1.73 vs $3.72; GAAP EPS $0.48; cuts FY outlook to ~$9.25
Q2 GAAP diluted EPS $0.48 (down 88% vs $4.09); adjusted EPS $1.73 (down 54% vs $3.72).
-
Bunge to sell 50% stake in BP Bunge Bioenergia JV for ~$800M
Bunge will sell its 50% interest in the BP Bunge Bioenergia JV to BP for an estimated net $800M.
-
Bunge shareholders approve 2024 LTIP, elect directors, and authorize $2.72 dividend
Shareholders approved 2024 Long-Term Incentive Plan, reserving 5,000,000 shares for future awards.
-
Bunge Q1 GAAP EPS $1.68 down 59% YoY; adj EPS $3.04; maintains FY ~$9 outlook
Q1 GAAP diluted EPS $1.68 vs $4.15 prior year; net income $244M down from $632M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.60 · Most common event debt